Quick Answer
FENNEC PHARMACEUTICALS INC. reported Net Income Loss of -$9.74 million for the year ending 2025.
- FENNEC PHARMACEUTICALS INC. showed a decrease of -2,134.2% in Net Income Loss from 2024 to 2025.
- This data is from FENNEC PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2004 to 2025 (22 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 22 years of available data (2004 to 2025), FENNEC PHARMACEUTICALS INC.'s Net Income Loss has declined by 41.7%.
- Historical annual values: Fiscal year 2025: -$9.74 million | Fiscal year 2024: -$436.0 thousand | Fiscal year 2023: -$16.05 million | Fiscal year 2022: -$23.71 million | Fiscal year 2021: -$17.35 million | Fiscal year 2020: -$18.11 million | Fiscal year 2019: -$12.78 million | Fiscal year 2018: -$9.89 million | Fiscal year 2017: -$7.05 million | Fiscal year 2016: -$2.79 million | Fiscal year 2015: -$659.0 thousand | Fiscal year 2014: -$2.18 million | Fiscal year 2013: $1.85 million | Fiscal year 2012: -$5.16 million | Fiscal year 2011: $4.69 million | Fiscal year 2010: -$7.82 million | Fiscal year 2009: -$3.01 million | Fiscal year 2008: -$13.60 million | Fiscal year 2007: -$13.36 million | Fiscal year 2006: -$16.44 million | Fiscal year 2005: -$13.87 million | Fiscal year 2004: -$6.87 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: